Brotizolam

CHEMBL32479 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

393.7 g/mol

LogP

2.8

Phase

4

A thienodiazepine drug with sedative, hypnotic, and anxiolytic properties, used in some countries for the short-term treatment of insomnia and anxiety. It acts on GABA-A receptors similarly to benzodiazepines to promote sleep and reduce anxiety. Risk of tolerance, dependence, and withdrawal limits its use to short-term treatment.

Masse moléculaire

393,7000 g/mol

LogP

2,80

TPSA

71,30 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Schizophrenia Generalized Anxiety Disorder Insomnia

Mécanisme d'action

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1nnc2n1-c1sc(Br)cc1C(c1ccccc1Cl)=NC2

InChI

InChI=1S/C15H10BrClN4S/c1-8-19-20-13-7-18-14(9-4-2-3-5-11(9)17)10-6-12(16)22-15(10)21(8)13/h2-6H,7H2,1H3

Molecular Formula

C15H10BrClN4S

HBD / HBA

- / 4

Liaisons Rotatives

1

Atomes Lourds

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A thienodiazepine drug with sedative, hypnotic, and anxiolytic properties, used in some countries for the short-term treatment of insomnia and anxiety. It acts on GABA-A receptors similarly to benzodiazepines to promote sleep and reduce anxiety. Risk of tolerance, dependence, and withdrawal limits its use to short-term treatment.

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Yes, Brotizolam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL32479. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2451. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Brotizolam sur PillFYI

Structure

Données Clés

Formule: C15H10BrClN4S

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.